Taken together, our study demonstrated for the first time that the FGF7/FGFR2-triggered signalling pathway, involving RSK2 activity and targeting PR, may be a new mechanism of breast cancer progression in response to stromal (e.g. cancer-associated fibroblasts) stimuli toward steroid hormone negative BCa. The gene discussed is FGF7; the disease is cancer.